| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5876068 | The American Journal of Medicine | 2016 | 29 Pages |
Abstract
Baseline HbA1c is associated with increased risk of macrovascular events but not hospitalization for heart failure. There was no heterogeneity in the effect of saxagliptin on cardiovascular events by baseline HbA1c, with cardiovascular death, myocardial infarction, or ischemic stroke neither increased nor decreased across the spectrum of baseline HbA1c values.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Matthew A. MD, MPH, Benjamin M. MD, MPH, Itamar MD, Ph. MD, Darren K. MD, MHSc, Lawrence A. MD, Boaz MD, Jaime MD, Avivit MD, Ofri MD, KyungAh PhD, Eugene MD, Deepak L. MD, MPH,